Abstract
Introduction As the US Food and Drug Administration (FDA) evaluates implementing a ban on menthol cigarettes and cigars, it is critical to estimate the potential public health effects of such a ban. With high rates of menthol cigarette use by the non-Hispanic Black (NHB) population and important smoking-related health disparity implications, the impact of the ban on this population merits strong consideration.
Methods We apply the previously developed Menthol Smoking and Vaping Model. A Status Quo Scenario is developed using population, smoking and vaping data specific to the NHB population. Estimates from a recent expert elicitation on behavioral impacts of a menthol cigarette ban on the NHB population are used to develop a Menthol Ban Scenario implemented in 2021. The public health impacts of the menthol ban are estimated as the difference between smoking and vaping attributable deaths (SVADs) and life years lost (LYLs) in the Status Quo and the Menthol Ban Scenarios from 2021-2060.
Results Under the Menthol Ban Scenario, overall smoking is projected to decline by 35.1% in 2026, and by 24.0% in 2060 relative to the Status Quo Scenario. With these reductions, SVADs are estimated to fall by about 18.5% and LYLs by 22.1%, translating to 255,000 premature deaths averted, and 3.9 million life-years gained over a 40-year period.
Conclusions A menthol cigarette ban will substantially reduce the smoking-associated health impact on the NHB population thereby reducing health disparities.
INTRODUCTION
Menthol represents 35% of US cigarette sales1 and menthol smoking is associated with higher smoking initiation and lower cessation.2-5 The US Food and Drug Administration (FDA) has proposed a nationwide ban on menthol cigarettes and cigars,6 but will be required to assess its potential public health impact.7,8
The Menthol Smoking and Vaping Model (SAVM) estimated the public health impact of a menthol ban on the total US population.9,10 However, the model did not explicitly distinguish the impact of the ban on the non-Hispanic Black (NHB) population. Due to their high rates of menthol cigarette use11,12,13 and important smoking-related health disparity implications,14,15 we apply the previously-developed Menthol SAVM10 to evaluate the impact of a menthol cigarette ban on the NHB population.
METHODS
The SAVM is a publicly available model16 which simulates the public health impact of cigarette and nicotine vaping product (NVP) use.17 Upon distinguishing menthol and non-menthol cigarette use, menthol SAVM10 projects averted deaths and life-years lost (LYLs) from 2013-2016 under Status Quo and Menthol Ban Scenarios. Further model details can be found elsewhere.10
Status Quo Scenario
The NHB observed and projected population and overall mortality rate by single year of age and sex were obtained from CDC Wonder18,19 and the US Census Bureau.20,21
To initialize the model, menthol and non-menthol NHB smoking prevalence by age and sex are from the 2013/14 Population Assessment of Tobacco and Health (PATH) survey,22 with menthol smoking defined as the regular brand flavored to taste like menthol. Current smoking is defined as having smoked >100 cigarettes during one’s lifetime and currently smoking at least some days. Smokers become former smokers after having quit for two years, thereby reflecting cessation net of relapse. Regular NVP use is defined in terms of at least 10 days use in the last month.
SAVM24 projects never, current, and former smoking prevalence using age-and sex-specific initiation and cessation rates estimated by applying an age-period-cohort model to the NHIS.25-28 Using prevalence estimates from the 2014/15 CPS-TUS to calibrate to NHB smoking initiation, we scaled US cigarette initiation rates by 0.91, calculated as the ratio of NHB ages 18-34 to total US ages 18-34 smoking prevalence. To calibrate NHB smoking cessation, we scaled US cessation rates by 0.81, calculated as the ratio of the total US ages 35+ to NHB ages 35+ smoking prevalence.
The proportion of menthol smokers among NHB smokers at age 30 (males 87.8%; females 86.3%), the age at which menthol and non-menthol prevalence rates tended to stabilize, is applied to smoking initiation rates to distinguish menthol and non-menthol smokers. To distinguish NHB menthol vs non-menthol cessation rates, we applied results of a meta-analysis,29 which reported that NHB menthol smokers had 12% lower odds of cessation than non-menthol smokers. Similar results were reported by Brouwer et al.30
To determine NHB death rates by smoking status, the ratio of NHB to total US population death rates was applied to US never, current, and former smoker death rates.25,26,31 Mortality rates of menthol and non-menthol smokers are not distinguished, given limited evidence of differences.32,33 To estimate life expectancy for the NHB population, the ratio of 2016 NHB never smokers life expectancy34 to 2016 US life expectancy25,26,31 was applied to the US life expectancy for the years 2013-2060.
Transitions to NVP use start in 2013. Recent studies29,35-38 report lower rates of NVP use among NHB adults than the total adult population. Based on the results from Usidame et al.,38 we scaled US NVP prevalence by 70% for the NHB population. Based on lower transition rates from cigarette use to exclusive NVP use among NHB menthol and non-menthol smokers (0.3% and 0.6%) reported by Brouwer et al.,30 we estimated NHB menthol smokers switch from smoking to vaping at 50% the rate of non-menthol smokers.
Menthol Ban Scenario
We model a federal menthol cigarette ban implemented in 2021. An expert elicitation on the impact of a menthol ban9 estimated that, of the NHB population who would otherwise initiate into menthol smoking in the absence of a ban, 34.0% would instead become non-menthol smokers, 2.9% illicit menthol smokers, 14.1% NVP users, and 49.0% would not use cigarettes or NVPs. These transitions are applied in the model to the initiation rates of otherwise NHB menthol smokers in 2021 and all future years. Among current NHB menthol smokers ages 18-24, experts expected 9.4% to switch to illicit menthol combustibles, 43.7% to non-menthol combustibles, 23.4% to NVPs and 23.4% to quit all product use.9 These transitions are applied to those who were current NHB menthol smokers through age 30 in 2021. Among NHB menthol smokers ages 35-54, experts expected 8.7% to switch to illicit menthol combustibles, 50.9% to non-menthol cigarette use, 15.3% to NVPs, and 25.1% to quit all product use.9 These transitions are applied to age 30+ current NHB menthol smokers in 2021. Current non-menthol smokers are unaffected except for those menthol smokers who switch to non-menthol use.
Outcomes
We estimate the public health impact of a menthol ban as the differences in smoking-and-vaping-attributable deaths (SVADs) and LYLs in the Status Quo and Menthol Ban Scenarios over 2021-2060. Smoking-attributable deaths are estimated as the excess mortality risk for current and former smokers multiplied by their respective populations. Vaping-attributable deaths are estimated assuming 15% of excess smoking risks.39,40 Total LYLs are estimated by the number of SVADs multiplied by the expected years of life remaining of a never smoker.
Validation
We validated pre-ban NHB menthol and non-menthol smoking rate trends against recent evidence from Mattingly et al.,41 which was consistent with an earlier study.23 Our model projected approximately a 20% decline in NHB adult menthol smoking during the first 5 years (2013-2018) consistent with the 20% decline reported by Mattingly et al.41 from 2010-2015. Our 2015 NHB menthol smoking prevalence of 12% is also consistent with Mattingly et al.41
RESULTS
Table 1 shows menthol and non-menthol smoking and NVP prevalence, SVADs and LYLs for NHB adults (ages >18). Under the Status Quo, NHB menthol smoking prevalence declines from 12.1% in 2021 to 9.8% in 2026 and 4.4% in 2060, while non-menthol smoking prevalence declines from 2.2% in 2021 to 1.6% in 2026 and 0.6% in 2060. Cumulative SVADs from 2021-2060 of 1,382,385 translate to 17,847,140 LYLs. Under the Menthol Ban, NHB adult menthol smoking prevalence declines from 12.1% in 2021 to 0.7% in 2026 and 0.2% in 2060, while non-menthol smoking prevalence increases from 2.2% in 2021 to 6.7% in 2026 and declines to 3.6% in 2060. Cumulative SVADs of 1,127,270 translate to 13,899,028 LYLs. Comparing the Status Quo and Menthol Ban Scenarios, the model projects 255,115 SVADs and 3,948,112 LYLs averted from 2021-2060.
DISCUSSION
A menthol cigarette ban implemented in 2021 would result in reductions in menthol and non-menthol cigarette use of 35% in 2026 and 24% in 2060. While NVP and non-menthol cigarette use would increase, 255,000 premature deaths would be averted (almost 6,300 per year) and 3.9 million life-years gained (almost 99,000 per year) by 2060.
The ban impact on the NHB population compares favorably to projections for the overall US population.10 We found that the ban leads to relative reduction in NHB adult smoking prevalence of 35.1% compared to 14.7% for the US.10 The percentage reduction in cumulative NHB averted deaths from 2021-2060 is 18.5% compared to 4.6% for the US,10 with a 22.1% relative reduction in NHB cumulative LYLs compared to 7.9% for the US.10 Thus, our analysis indicates that a menthol ban would also reduce smoking-related health disparities. Our results are also consistent with earlier modeling results that find disproportionately greater health impacts on the NHB than the general population from a menthol cigarette ban42 and past menthol use.43,44
Our findings are dependent on the model structure, parameters, and assumptions. While we calibrated the model to smoking and NVP rates, smoking and NVP rates have been subject to recent instability,45,46 including in the NHB population.47,48 In addition, the model does not distinguish the health impact of exclusive menthol cigarette smokers who switch to cigar use as a result of a menthol ban. For a ban to be effective, especially as it relates to the NHB population, it will be important that it is applied to both menthol cigarettes and flavored cigars, since little cigars are a close substitute for cigarettes.49-51 A ban on menthol cigars would yield additional health gains, especially to the NHB population. However, the impact may be reduced if a ban is also imposed on menthol and mint NVP flavored e-cigarettes, since menthol smokers may be less likely to quit smoking in their absence. Finally, the results are also subject to uncertainties regarding impacts of a menthol ban. The effects of a menthol ban on smoking initiation and cessation were based on results of an expert elicitation, and thus dependent on the participating reviewers’ assessments and the process applied in the elicitation.9
Our study strongly supports the implementation of a ban on menthol in cigarettes on public health and especially health equity grounds for the NHB population.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
What This Paper Adds
The Food and Drug Administration is intending a ban on menthol cigarettes and cigars, and it is critical to show the effect of such a ban on public health. With high rates of menthol cigarette use by the NHB population and important smoking-related health disparity implications, the impact of a menthol ban on NHB individuals merits strong consideration. This study evaluates the public health impacts of a menthol ban on the NHB population.
The public health implications of a ban on the non-Hispanic Black population have not been considered.
With a ban on menthol in cigarettes implemented in 2021, NHB adult smoking and vaping attributable deaths are estimated to fall by about 18.5% and years of life lost by 22.1% by 2060, translating to 255,000 premature deaths averted, and 3.9 million life-years gained.
Our findings strongly support the implementation of a ban on menthol in cigarettes and cigars, resulting simultaneously in considerable health gains and in reductions in health disparities between the NHB and the rest of the US population.
Acknowledgments
We would like to thank the Center for the Assessment of Tobacco Regulations (CAsToR) Data Analysis and Dissemination Core for providing data for this work. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health (NIH) and FDA Center for Tobacco Products (CTP) under Award Number U54CA229974. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or FDA.
References
